BIOGEN INC. - COMMON STOCK

Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

17 Oct 2022 07:30:10 By Nasdaq GlobeNewswire

Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)

30 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Pivotal Tofersen Data that Show Benefits in Rare, Genetic Form of ALS

21 Sep 2022 17:15:12 By Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Second Manuscript Reporting Positive Phase 2 Results for Biogen’s Litifilimab (BIIB059) in Lupus

07 Sep 2022 17:45:26 By Nasdaq GlobeNewswire

The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus

28 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS

26 Jul 2022 07:30:02 By Nasdaq GlobeNewswire

European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

21 Jun 2022 06:37:05 By Nasdaq GlobeNewswire

New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)

15 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities

14 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

06 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

03 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS

03 Jun 2022 05:20:00 By Nasdaq GlobeNewswire

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression

04 Apr 2022 16:06:00 By Nasdaq GlobeNewswire

Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA

30 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

28 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease

16 Mar 2022 11:54:52 By Nasdaq GlobeNewswire

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

16 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

14 Mar 2022 19:00:00 By Nasdaq GlobeNewswire

Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)

11 Mar 2022 16:30:00 By Nasdaq GlobeNewswire